Pyxis Oncology has concluded its first multi-target sublicensing agreement under the new arrangement with a stealth ADC company. This expansion builds on the former agreement, which provided Pyxis ...

Pyxis Oncology is slimming down after a tough start to life on public markets, pausing work on two assets and stopping development of a third altogether to focus its cash on getting its lead programs ...

Pyxis Oncology needs to pave a longer cash runway. To do so, the Pfizer-partnered antibody-drug conjugate (ADC) biotech is cutting 40% of staff, slimming its programs and looking to monetize royalty ...

We recently compiled a list of the 12 Penny Stocks with Insider Buying in 2026. Pyxis Tankers Inc. (NASDAQ:PXS) is one of the ...

Pyxis Oncology (NASDAQ:PYXS) is down ~38% in after-hours trading Wednesday after posting preliminary phase 1 data on PYX-201, an antibody-drug conjugate for solid tumors. The data presented was in six ...

Becton, Dickinson and Company BDX, popularly known as BD, recently announced the European launch of its BD Pyxis Pro ...

Stephens has initiated coverage on Pyxis Oncology Inc (NASDAQ:PYXS), highlighting the company’s technology platform aimed at developing next-gen antibody-drug conjugates (ADCs) with enhanced potency, ...

Pyxis Oncology (NASDAQ:PYXS) shares reached a new 52-week high as the clinical-stage biotech backed by pharma giant Pfizer (PFE) extended the recent winning streak into the fifth consecutive session, ...

Any time a business conference producer approaches the day when all the speakers and attendees get on airplanes and fly to the venue, things change fast. A speaker cancels and has to be replaced at ...